Three anti-VEGF therapies have long been mainstays of treatment in wet age-related macular degeneration (AMD)—Roche / Genentech’s Lucentis, Regeneron’s Eylea, and Roche / Genentech’s Avastin (used off-label). However, the market now stands poised to fragment as new therapies begin to launch, including Roche’s Susvimo and Vabysmo, which promise less frequent dosing and, in the case of the latter, a new mechanism of action. Several other therapies, such as Regeneron’s high-dose aflibercept and Kodiak Science’s KSI-301, are progressing through the pipeline, and entirely new therapeutic approaches, such as AbbVie / Regenxbio’s gene therapy RGX-314, are in late-phase development in the United States. To what extent will new therapies be used compared with the current standards of care, with which ophthalmologists are comfortable and familiar? Moreover, both current and novel therapies will face competition from the first biosimilars entering the market, starting in 2022 with Biogen / Samsung Bioepis’s Byooviz, a biosimilar to Lucentis. To what extent will biosimilars compete with originator brands and blunt the uptake of emerging therapies? Additionally, the first therapy to treat geographic atrophy, Apellis’s pegcetacoplan, is poised to launch in the U.S. market; to what extent do ophthalmologists expect to use this drug and in which patients?
Clarivate’s Special Topics reports use quantitative and/or qualitative primary research to assess evolving trends and market effects in dynamic disease areas. Insights from this report will help developers gauge the competitiveness and sales potential of late-phase assets in the AMD market.